CDNA (CareDx) Long-Term Debt: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDNA CareDx Inc CDNA
67 GF Score
Price $46.69
GF Value $25.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CareDx Long-Term Debt?

CareDx CDNA +4.20% 67 Long-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus rates CDNA with a GF Score™ of 67/100 and a GF Value™ of $25.23 (Significantly Overvalued). The stock has 7 warning signs investors should review.

CareDx's Long-Term Debt for the quarter that ended in Jun. 2026 was $0.0 Mil.

CareDx  (NAS:CDNA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

CareDx Long-Term Debt Related Terms

CareDx Long-Term Debt Historical Data

* Premium members only.

The historical data trend for CareDx's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CareDx Long-Term Debt Chart

CareDx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CareDx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CDNA
67GF Score
CareDx Inc CDNA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
CareDx (CDNA) has a Long-Term Debt of $0.0 Mil as of Jun. 2026.
Is CareDx's Long-Term Debt too high?
CareDx's current Long-Term Debt is $0.0 Mil. Overall, CareDx has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Long-Term Debt compare to NEO and WGS?
CareDx's Long-Term Debt of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. CareDx's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (CDNA) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.23, compared to a current price of $46.69 — trading 85.1% above its estimated fair value. The current Long-Term Debt is $0.0 Mil. CareDx's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For CareDx (CDNA), the current Long-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareDx (CDNA) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of $46.69 is trading 85.1% above its estimated GF Value™ of $25.23. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for CDNA:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $25.23 vs. price of $46.69 (85.1% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the CDNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CareDx Business Description

Other Exchanges 1K9:Germany
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
67GF Score

Get the complete analysis for CDNA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.69
Price
$25.23
GF Value